NEUREN PHARMACEUTICALS LIMITED DISCLOSURECurrent Reports (8-K / ad hoc)

Growing royalty anchors Neuren first ever dividend program

1 of 6 Neuren (NEU) – ASX Announcement 26 August 2026 Growing royalty income anchors Neuren’s first-ever dividend program Highlights: H1 2026 results • First-ever dividend program enhances total shareholder return, with semi-annual dividends anchored to growing royalty income • Interim dividend for H1 2026 of 15 cents per share fully franked • H1 2026 royalty income up 29% to US$23 million vs H1 2025 • Profit after tax A$4.9 million, cash and short-term investments A$287 million DAYBUE® (trofinetide) • H1 2026 net sales US$226 million, up 25% from H1 2025 driven by strong adoption of DAYBUE STIX • Acadia increased full year 2026 global net sales guidance to US$480-510 million and reaffirmed target global net sales in 2028 of US$700 million • European Commission granted marketing authorisation for DAYBU® - launch in Germany anticipated in early Q4 2026 • Results of Japan trial expected Sep to Nov 2026, with regulatory submission anticipated in 2027 NNZ-2591 (ercanetide) • 15 sites in US and Canada now enrolling for Koala Phase 3 clinical study in Phelan-McDermid syndrome (PMS) • 8 sites activated to date for the PMS open-label extension study, enabling transition of patients who have completed the placebo-controlled study • Type B End of Phase 2 face-to-face meeting with FDA for Pitt Hopkins syndrome confirmed for late Oct 2026 • Rare Pediatric Disease Priority Review Voucher program reauthorised by US Congress Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today declared a fully franked interim dividend for H1 2026 as part of the Company’s first ever dividend policy to enhance total shareholder return, anchored to Neuren’s growing royalty income from DAYBUE® (trofinetide). Neuren CEO Jon Pilcher commented: “Neuren’s substantial income from trofinetide means that we are in the enviable position of being able to fund all development programs for NNZ-2591 aiming for significant capital appreciation, as well as optimise total shareholder return through ongoing fully franked dividends.” The ongoing dividend policy targets a semi-annual payout ratio between 70% and 100% of the after-tax amount of Neuren’s royalty income less corporate and administrative costs (“Available Pool”). The Board has declared an interim dividend for H1 2026 of 15 cents per share representing 90% of the H1 For person